Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Gennaio 2024 - 2:00PM
Immunovant, Inc. (Nasdaq: IMVT),
a clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases, today announced that
Pete Salzmann, M.D., chief executive officer, will provide a
corporate overview at the 42nd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 9, 2024, at 10:30 am ET.
The presentation will be webcast live and can be
accessed at https://www.immunovant.com/investors/news-events. An
archived webcast will be available for a limited time on
Immunovant’s website.
About Immunovant, Inc.Immunovant,
Inc. is a clinical-stage immunology company dedicated to enabling
normal lives for people with autoimmune diseases. As a trailblazer
in anti-FcRn technology, the Company is developing innovative,
targeted therapies to meet the complex and variable needs of people
with autoimmune diseases. For additional information on the
Company, please visit www.immunovant.com.
Contact:Chau Cheng, PhD, MBAVice
President, Investor RelationsImmunovant,
Inc.info@immunovant.com
Grafico Azioni Immunovant (NASDAQ:IMVT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Immunovant (NASDAQ:IMVT)
Storico
Da Set 2023 a Set 2024